Leveraging the power of vaccines to prevent antimicrobial resistance
A new report from the World Health Organization (WHO) puts a spotlight on yet another downstream benefit of vaccines.
A new report from the World Health Organization (WHO) puts a spotlight on yet another downstream benefit of vaccines.
Vaccines are one of the most effective tools we have for protecting our health. They have a long track record of safety and efficacy and savings across the health system, and are responsible for significant improvements in public health, including the eradication of smallpox and the near elimination of diseases like polio and measles.
Now a new report from the World Health Organization (WHO) puts a spotlight on yet another downstream benefit of vaccines – their ability to lower antibiotic use, decrease resources spent treating resistant infections and reduce the global burden of antimicrobial resistance (AMR). Data show:
Increasing vaccine uptake can also drive substantial savings for the health care system – globally and here in the U.S.
Absent intervention, AMR could result in 39 million deaths between now and 2050, according to The Lancet. But thanks to the U.S. biopharmaceutical industry’s leading efforts to research and develop innovative vaccine technology, these powerful tools are protecting Americans and people around the globe from disease and helping mitigate the threat of long-term public health challenges like AMR.
Learn more about AMR here.